TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Benzinga Logo Benzinga • •By Vandana Singh
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Gilead Sciences reported mixed results from a Phase 3 breast cancer study of Trodelvy, which did not meet its primary endpoint of progression-free survival but showed an early trend in overall survival. The drug's safety profile remained consistent with previous studies.

Insights
GILD   neutral

Study results were mixed - missed primary endpoint but showed potential early survival trend, indicating neither a clear success nor complete failure